{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-24-000043","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.759859+00:00","generated_at":"2026-06-04T09:03:03.992098+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ivonescimab shows 34% intracranial response in NSCLC brain mets; median PFS 19.3 months","bullets":["Intracranial response rate 34% (23% complete) in NSCLC patients with brain metastases; median PFS 19.3 months.","Ivonescimab + chemo in 1L squamous NSCLC: median PFS 11.1 months; non-squamous: 13.3 months; OS not reached at 22.1 months.","No intracranial bleeding observed across cohorts; safety profile manageable with 11.1% discontinuation in squamous group.","Two Phase III trials ongoing: HARMONi (EGFR-mutant post-TKI) and HARMONi-3 (1L squamous NSCLC).","Data presented at ELCC 2024; posters available on company website."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-24-000043","json":"https://secwatch.observer/filing/0001599298-24-000043.json","markdown":"https://secwatch.observer/filing/0001599298-24-000043.md","text":"https://secwatch.observer/filing/0001599298-24-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000043/0001599298-24-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000043/smmt-20240322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:03:03.992098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}